
    
      The purpose of this study is to determine whether the addition of nivolumab to chemotherapy
      improves pathologic complete response (pCR) in the breast and post-therapy lymph nodes
      evaluated histologically (ypT0/Tis ypN0) in patients with inflammatory breast cancer (IBC).
    
  